ERBB2 and breast cancer: Abdel-Fatah et al. (2010), in the group of 245 patients with invasive BC treated with adjuvant ATC-based chemotherapy, found a good prognosis for patients with active or partially inactive P53 pathway (assessed by expression of BCL-2, p21, p27, hormone receptors, P53, Ki-67, EGFR, CK 5/6 and HER2 gene amplification status).